With cancellation of the preferential subscription rights through
an international private placement reserved for specialized or strategic investors.
Geneva, Switzerland, February 2, 2024 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the successful completion of a €5 million capital increase with cancellation of the preferential subscription rights through an international private placement reserved for specialized or strategic investors of (the “Private Placement”) 4,666,901 new ordinary bearer shares of GeNeuro and through a public offering for retail investors in France via the PrimaryBid platform (the “PrimaryBid Offer”, and together with the Private Placement, the “Offering”) of 95,004 new ordinary bearer shares of GeNeuro. All new ordinary shares have a par value of CHF 0.05 each (the “New Shares”).